EBS insider transaction filings
Emergent BioSolutions Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-07-02. Screen EBS transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-02 | 4 | Williams Paul Anthony — SVP, Products Business | Sale (S): 3,000 @ $8.40 | EDGAR |
| 2026-06-10 | 4 | Hartzel William — SVP, Bioservices | Tax withholding (F): 1,741 @ $8 | EDGAR |
| 2026-06-10 | 4 | Williams Paul Anthony — SVP, Products Business | Tax withholding (F): 694 @ $8 | EDGAR |
| 2026-06-10 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Tax withholding (F): 2,018 @ $8 | EDGAR |
| 2026-06-10 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Tax withholding (F): 3,964 @ $8 | EDGAR |
| 2026-05-04 | 4 | Zoon Kathryn C — Director | Grant/award (A): 25,344 @ $0 · Sale (S): 16,145 @ $8.36 · Sale (S): 1,057 @ $8.97 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | DeGolyer Donald W — Director | Grant/award (A): 25,344 @ $0 · Sale (S): 14,527 @ $8.36 · Sale (S): 954 @ $8.96 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Dayal Sujata Tyagi — Director | Grant/award (A): 25,344 @ $0 · Sale (S): 12,781 @ $8.36 · Sale (S): 980 @ $8.94 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Fowler Neal Franklin — Director | Grant/award (A): 25,344 @ $0 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | White Marvin L — Director | Grant/award (A): 25,344 @ $0 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Harsanyi Zsolt — Chairman, Director | Grant/award (A): 25,344 @ $0 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Richard Ronald — Director | Grant/award (A): 25,344 @ $0 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | Katkin Keith — Director | Grant/award (A): 25,344 @ $0 · Sale (S): 15,481 @ $8.28 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-04 | 4 | FOWLER JOHN D JR — Director | Grant/award (A): 25,344 @ $0 · Grant/award (A): 11,296 (derivative) @ $0 | EDGAR |
| 2026-05-01 | 4 | Lowry Simon C — SVP, R&D, CMO | Grant/award (A): 100,111 @ $0 | EDGAR |
| 2026-05-01 | 4 | Perl Jessica — SVP, General Counsel, Corp Sec | Grant/award (A): 104,282 @ $0 | EDGAR |
| 2026-05-01 | 4 | Hartzel William — SVP, Bioservices | Grant/award (A): 100,111 @ $0 | EDGAR |
| 2026-05-01 | 4 | Williams Paul Anthony — SVP, Products Business | Grant/award (A): 100,111 @ $0 | EDGAR |
| 2026-05-01 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Grant/award (A): 100,111 @ $0 | EDGAR |
| 2026-05-01 | 4 | PAPA JOSEPH C — President and CEO, Director | Grant/award (A): 187,708 @ $0 | EDGAR |
| 2026-05-01 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Grant/award (A): 162,680 @ $0 | EDGAR |
| 2026-04-03 | 4 | Williams Paul Anthony — SVP, Products Business | Sale (S): 4,000 @ $8.44 | EDGAR |
| 2026-03-06 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Code (H): 19,963 (derivative) @ $0 · Code (H): 20,321 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Lowry Simon C — SVP, R&D, CMO | Tax withholding (F): 10,636 @ $8.44 · Grant/award (A): 44,834 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Perl Jessica — SVP, General Counsel, Corp Sec | Tax withholding (F): 6,465 @ $8.44 · Grant/award (A): 46,702 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Hartzel William — SVP, Bioservices | Tax withholding (F): 9,493 @ $8.44 · Grant/award (A): 44,834 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Williams Paul Anthony — SVP, Products Business | Tax withholding (F): 9,397 @ $8.44 · Grant/award (A): 44,834 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Tax withholding (F): 8,199 @ $8.44 · Grant/award (A): 44,834 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | PAPA JOSEPH C — President and CEO, Director | Tax withholding (F): 37,055 @ $8.44 · Grant/award (A): 252,194 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Tax withholding (F): 23,650 @ $8.44 · Grant/award (A): 72,856 (derivative) @ $0 | EDGAR |
| 2026-03-05 | 4 | FOWLER JOHN D JR — Director | Grant/award (A): 5,006 @ $8.99 | EDGAR |
| 2026-03-03 | 4 | Williams Paul Anthony — SVP, Products Business | Tax withholding (F): 116 @ $8.15 | EDGAR |
| 2026-03-03 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Tax withholding (F): 313 @ $8.15 | EDGAR |
| 2026-03-03 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Tax withholding (F): 683 @ $8.15 | EDGAR |
| 2026-02-10 | 4 | Perl Jessica — SVP, General Counsel, Corp Sec | Tax withholding (F): 918 @ $11.03 | EDGAR |
| 2026-02-10 | 4 | Hartzel William — SVP, Bioservices | Disposition to issuer (D): 5,771 @ $10.92 · Tax withholding (F): 630 @ $10.92 | EDGAR |
| 2026-02-10 | 4 | Williams Paul Anthony — SVP, Products Business | Disposition to issuer (D): 8,655 @ $10.92 · Tax withholding (F): 1,022 @ $10.92 | EDGAR |
| 2026-02-10 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Disposition to issuer (D): 28,847 @ $10.92 · Tax withholding (F): 2,852 @ $10.92 | EDGAR |
| 2026-02-10 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Disposition to issuer (D): 46,155 @ $10.92 · Tax withholding (F): 5,642 @ $10.92 | EDGAR |
| 2025-12-16 | 4 | Lowry Simon C — SVP, R&D, CMO | Tax withholding (F): 3,543 @ $11.41 | EDGAR |
| 2025-12-09 | 4 | Richard Ronald — Director | Sale (S): 7,100 @ $12.11 · Option exercise (M): 25,748 @ $5.02 · Tax withholding (F): 10,864 @ $11.90 · Sale (S): 14,884 @ $11.90 · Option exercise (M): 25,748 (derivative) @ $0 | EDGAR |
| 2025-11-13 | 4 | Hartzel William — SVP, Bioservices | Tax withholding (F): 610 @ $10.88 | EDGAR |
| 2025-11-12 | 4 | DeGolyer Donald W — Director | Sale (S): 17,801 @ $10.54 | EDGAR |
| 2025-11-10 | 4 | Dayal Sujata Tyagi — Director | Sale (S): 8,552 @ $10 | EDGAR |
| 2025-10-17 | 4 | LINDAHL RICHARD S — EVP, Chief Financial Officer | Tax withholding (F): 4,995 @ $9.60 | EDGAR |
| 2025-10-16 | 4 | Glessner Coleen — EVP, Quality & Ethics, and CPL | Sale (S): 30,608 @ $10 | EDGAR |
| 2025-08-18 | 4 | Zoon Kathryn C — Director | Sale (S): 7,086 @ $8.87 | EDGAR |
| 2025-08-13 | 4 | DeGolyer Donald W — Director | Sale (S): 7,844 @ $8.65 | EDGAR |
| 2025-07-15 | 4 | Hartzel William — SVP, Bioservices | Tax withholding (F): 4,263 @ $7.36 | EDGAR |
| 2025-06-10 | 4 | Hartzel William — SVP, Bioservices | Tax withholding (F): 1,167 @ $6.63 | EDGAR |
Recent 8-K events — Emergent BioSolutions Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition ? 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-30 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-14 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-12 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=EBS returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →